Insider Buying: GSK plc (LON:GSK) Insider Acquires 8 Shares of Stock

GSK plc (LON:GSK) insider Julie Brown purchased 8 shares of the company’s stock in a transaction that occurred on Friday, August 9th. The shares were purchased at an average price of GBX 1,505 ($19.22) per share, for a total transaction of £120.40 ($153.73).

Julie Brown also recently made the following trade(s):

• On Tuesday, June 11th, Julie Brown acquired 8 shares of GSK stock. The stock was purchased at an average price of GBX 1,623 ($20.72) per share, with a total value of £129.84 ($165.78).

GSK Stock Up 0.3 %

Shares of GSK stock opened at GBX 1,597.50 ($20.40) on Thursday. The company has a 50-day simple moving average of GBX 1,554.42 and a two-hundred day simple moving average of GBX 1,636.22. The stock has a market capitalization of £65.18 billion, a PE ratio of 1,413.72, a price-to-earnings-growth ratio of 1.45 and a beta of 0.29. GSK plc has a 52-week low of GBX 1,340 ($17.11) and a 52-week high of GBX 1,823.50 ($23.28). The company has a debt-to-equity ratio of 123.04, a quick ratio of 0.73 and a current ratio of 0.82.

GSK Announces Dividend

The company also recently disclosed a dividend, which will be paid on Thursday, October 10th. Investors of record on Thursday, August 15th will be issued a GBX 15 ($0.19) dividend. The ex-dividend date of this dividend is Thursday, August 15th. This represents a yield of 0.97%. GSK’s payout ratio is currently 5,309.73%.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on GSK. Barclays reaffirmed an “equal weight” rating and issued a GBX 1,725 ($22.03) target price on shares of GSK in a research report on Tuesday, May 7th. Citigroup cut their price objective on shares of GSK from GBX 2,120 ($27.07) to GBX 1,900 ($24.26) and set a “buy” rating on the stock in a report on Friday, July 5th. Jefferies Financial Group reiterated a “buy” rating and set a GBX 2,100 ($26.81) target price on shares of GSK in a report on Thursday, June 27th. Deutsche Bank Aktiengesellschaft dropped their price target on GSK from GBX 1,950 ($24.90) to GBX 1,850 ($23.62) and set a “buy” rating on the stock in a research report on Wednesday, July 31st. Finally, Shore Capital reaffirmed a “buy” rating on shares of GSK in a research report on Thursday, June 27th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of GBX 1,805.71 ($23.06).

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.